Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: FDA and I-MAK; Table: Naema Ahmed/Axios

Some of the best-selling drugs in the U.S. have stacked up extra federal protections that were initially intended to spark research into drugs that couldn’t make money on their own.

Why it matters: Some experts fear that these additional protections could help shield blockbuster drugs from cheaper competitors.

How it works: Federal law gives drug companies an extra incentive to research treatments for “orphan” diseases — conditions that affect fewer than 200,000 people and thus don't present a compelling business opportunity for drugmakers.

  • If a drug treats an orphan disease, it can get 7 years of additional market exclusivity, free from generic competitors, for that use.

By the numbers: 6 of the 8 best-selling biologic drugs in 2017 have orphan approvals, and 3 — Humira, Rituxan and Avastin — still have extra exclusivity for some of those uses.

Between the lines: Most of these drugs don’t yet face competition from biosimilars — which are similar to generics, but aren’t automatically interchangeable at the pharmacy counter.

  • Some experts fear, however, that even once there’s a competitive biosimilars market in the U.S., these orphan approvals will give biologics a leg up — even though these orphan approvals don't legally bar biosimilars from competing on other uses.
  • “I think it really is all about...being able to maintain your market share for the orphan indication as well as the indication for which your product is being used…it just might make it less likely that competitors come onto the market,” Vanderbilt's Stacie Dusetzina said.

The other side: Drugmakers say that’s not the case.

  • "These exclusivities will not prevent Humira biosimilars from entering the market. In fact, biosimilars will enter the market for the non-orphan indications two years before the latest Humira orphan-designated indication exclusivity expires," said MK Steel, a spokeswoman for AbbVie, which makes Humira, the world’s best-selling drug.
  • "We’re proud to have studied [Remicade] in orphan indications. These are small populations with large unmet need," said Linda Davis, a Janssen spokeswoman, adding that all of Remicade's orphan exclusivity periods have expired.

In the end, it’ll be up to insurance companies and providers to decide whether an orphan approval makes a biologic more desirable than a biosimilar, even for the non-orphan uses that drive most sales.

  • “It may be giving already marketed drugs a commercial advantage...but that’s why we have payers and [pharmacy benefit managers]. They're supposed to be negotiating,” Food and Drug Administration Commissioner Scott Gottlieb said.

What’s next: Some critics say drugs that are already raking billions shouldn’t be able to rack up so much extra protection in the first place. And change may be coming.

  • “For a drug that’s already on the market, maybe you don’t need as much incentive to study a subsequent indication," Gottlieb said. "Maybe we make the designation harder to get.”
  • “I think with these big established drugs, there needs to be a streamlined way of giving enough incentive for it to be used in a smaller population, but not necessarily the system that we have now," said Ted Okon, executive director of the Community Oncology Alliance.

The bottom line: “These are examples of drugs where the financial returns absolutely appear to be there," Dusetzina said. “They’re not meeting the spirit of the law, even if they’re technically meeting the letter of the law.”

Go deeper

Kendall Baker, author of Sports
1 hour ago - Sports

2021 Tokyo Olympics hang in the balance

Illustration: Aïda Amer/Axios

10 months ago, the Tokyo Olympics were postponed. Now, less than six months ahead of their new start date, the dreaded word is being murmured: "canceled."

Driving the news: The Japanese government has privately concluded that the Games will have to be called off, The Times reports (subscription), citing an unnamed senior government source.

Biden's centrist words, liberal actions

Illustration: Sarah Grillo/Axios

President Biden talks like a soothing centrist. He promises to govern like a soothing centrist. But early moves show that he is keeping his promise to advance a liberal agenda.

Why it matters: Never before has a president done more by executive fiat in such a short period of time than Biden. And those specific actions, coupled with a push for a more progressive slate of regulators and advisers, look more like the Biden of the Democratic primary than the unity-and-restraint Biden of the general election.

3 hours ago - Technology

Review of Trump ban marks major turning point for Facebook

Photo Illustration: Aïda Amer/Axios. Photo: Saul Loeb/AFP via Getty Images

Facebook's decision to ask its new independent Oversight Board to review the company's indefinite suspension of former President Trump is likely to set a critical precedent for how the social media giant handles political speech from world leaders.

What they're saying: "I very much hope and can expect … that they will uphold our decision," Facebook's VP of global affairs Nick Clegg tells Axios.